Clinical Trial Update: Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update for Mirvetuximab soravtansine (IMGN853) in FRα-high recurrent ovarian, fallopian tube, or primary peritoneal cancer. The study s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Mirvetuximab soravtansine (IMGN853) (mirvetuximab soravtansine)

Snippet

Sponsor: AGO Research GmbH | Conditions: Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING